Abstract 666

Background.

Dasatinib (Sprycel®, Bristol-Myers Squibb) is a potent multi-targeted kinase inhibitor (TKI) of BCR-ABL and SRC family kinases. The EWALL group for adult ALL decided to run a study at the European level evaluating the combination of dasatinib and chemotherapy for Philadelphia positive (Ph+) ALL patients (pts) aged 55 and over.

Aim.

To analyse efficacy of Dasatinib combined to low intensity chemotherapy and to test factors associated with outcome. (EudraCT 2006–005694-21).

Methods.

After prephase, dasatinib was administered at 140 mg QD (100 mg over 70y) during the induction period in combination with weekly vincristine (VCR) 1 mg IV and dexamethasone (DEX) 40 mg for 2 days (20 mg over 70y) for 4 weeks. Consolidation

graphic
View largeDownload slide
Disclosures:

Rousselot:BMS, Novartis: Research Funding. Gambacorti-Passerini:BMS, Novartis: Research Funding.

Topics:
chemotherapy regimen, dasatinib, bcr-abl tyrosine kinase, brachial plexus neuritis, dexamethasone, kinase inhibitors, protein-tyrosine kinase inhibitor, src-family kinases, vincristine

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2012 by The American Society of Hematology
2012
Sign in via your Institution